Table 2.
Results of laboratory investigations
| Patient A | Patient B | Patient C | |
|---|---|---|---|
| PTH | 1.5 × ULN (12.4 pmol/L, rr 0.8–8.0) |
3.0 × ULN (20 pmol/L, rr 1.5-6.9) |
1.2 × ULN ( 8.8 pmol/L, rr 1.6-7.2) |
| Corrected calcium | 1.9 × ULN (2.92 mmol/L, rr 2.16-2.45) |
1.2 × ULN (3.06 mmol/L, rr < 2.55) |
Normal |
| 25OHD | Normal | Normal | 0.4 × LLN (24 nmol/L, rr > 50) |
| TSH | Normal | Normal | Normal |
| Prolactin | 3.8 × ULN (1898 mIU > L, rr 50-500) |
Normal | Normal |
| IGF-1 | 1.0 × ULN (251 µg/L, rr 93-245) |
Normal | 1.2 × ULN (49 nmol/L, rr 8-42) |
| GH | Normal | Normal | Normal |
| ACTH | Normal | Normal | 1.5 × ULN (21 pmol/L, rr < 14) |
| Cortisol | 1.3 × ULN | Normal | Normal |
| Morning (600 am) | (699 nmol/L, rr 100-535) (initial) Normal (490 nmol/L) (repeat) |
- | - |
| Midnight salivary |
1.1 × ULN (3.6 nmol/L, rr < 3.2) |
- | - |
| 24-h urinary excretion (preoperative) | 2.3 × ULN (624 nmol/L, rr < 270) |
- | 2.9 × ULN (438 nmol/24h, rr < 150) |
| 24-h urinary excretion (postoperative) | - | - | Normal |
| 1 mg DST | 1.2 × ULN (62 nmol/L, rr < 50) |
- | 5 × ULN (249 nmol/L, rr < 50) |
| DHEAS | 1.6 × ULN (11.3 µmol/L, rr 1.0-7.0) |
- | - |
| Androstenedione | Normal | - | - |
| HbA1c% | Normal | - | 1.2 × ULN (6.7%, rr < 5.6%) |
| CgA | Normal | Normal | Normal |
| Gastrin | Normal | Normal | Normal |
| 5HIAA | |||
| Preoperative | - | - | 1.5 × ULN (53 µmol/24 h, rr < 35) |
| Postoperative | - | - | Normal |
| c-peptide | - | - | 1.5 × ULN (2.3 nmol/L, rr 0.4-1.5) |
| Insulin | - | Normal | N/A |
| VIP | Normal | Normal | N/A |
| Glucagon | Normal | Normal | N/A |
| Pancreatic polypeptide | Normal | 1.4 × ULN (78.1 pmol/L, rr < 55) |
N/A |
Abbreviations: -, not performed; 5HIAA, 5-hydroxyindoleacetic acid; CgA, chromogranin A; DHEAS, dehydroepiandrosterone sulfate; DST, dexamethasone suppression test; HbA1c, glycated hemoglobin; N/A, performed but not available; rr, reference range; ULN, upper limit of normal; VIP, vasoactive intestinal peptide.